期刊文献+

人参皂苷对骨肉瘤患者血清VEGF及TSGF水平的影响及临床疗效 被引量:9

Effect of Ginsenoside on the Serum VEGF and TSGF Levels and Clinical Efficacy of Patients with Osteosarcoma
原文传递
导出
摘要 目的:探讨人参皂苷对骨肉瘤患者血清血管内皮生长因子(VEGF)、肿瘤特异性生长因子(TSGF)的影响及临床疗效。方法:收集我院收治的骨肉瘤患者60例,根据用药不同分为对照组和实验组,每组30例。对照组采用FOLFOX4方案化疗,实验组在对照组基础上加用人参皂苷治疗。观察并比较两组患者治疗前后的肿瘤体积、血清VEGF及TSGF水平变化以及临床疗效。结果:与治疗前比较,两组患者治疗后的肿瘤体积均显著减小,血清VEGF及TSGF水平均显著下降,差异具有统计学意义(P<0.05);与对照组相比,实验组患者治疗后肿瘤体积减小更明显,血清VEGF及TSGF水平下降更显著,差异具有统计学意义(P<0.05);实验组患者治疗总有效率(80.0%)显著高于对照组(46.67%),差异具有统计学意义(P=0.009)。结论:人参皂苷能够显著降低骨肉瘤患者血清VEGF及TSGF水平,减小肿瘤体积,临床疗效显著。 Objective:To investigate the effect of Ginsenoside on the serum VEGF,TSGF levels and clinical efficacy of patients with osteosarcoma.Methods:60 patients with osteosarcoma who were treated in our hospital were selected and divided into two groups according to different treatment,with 30 cases in each group.The patients in the control group were treated with FOLFOX4 regime,while the patients in the experimental group were treated with FOLFOX4 regime combined with ginsenoside.Then the tumor volume,serum levels of VEGF and TSGF and efficacy in the two groups were observed and compared before and after the treatment.Results:Compared with the treatment,the tumor volume,the serum levels of VEGF and TSGF significantly decreased,and the difference was statistically significant(P0.05);compared with the control group,the serum levels of VEGF and TSGF decreased significantly,and the difference was statistically significant(P0.05);the total effective rate in the experimental group(80.0%) was significantly higher than that of the control group(46.67%),and the difference was statistically significant(P=0.009).Conclusion:Ginsenoside could significantly reduce the serum levels of VEGF and TSGF and tumor volume of patients with osteosarcoma,which could promote the clinical efficacy.
出处 《现代生物医学进展》 CAS 2016年第6期1067-1069,1072,共4页 Progress in Modern Biomedicine
基金 辽宁省教育厅科技研究项目(2008557)
关键词 人参皂苷 骨肉瘤 血清血管内皮生长因子 肿瘤特异性生长因子 临床疗效 Ginsenoside Osteosarcoma VEGF TSGF Clinical efficacy
  • 相关文献

参考文献20

  • 1Bemardini G, Laschi M, Geminiani M, et al. Proteomics of osteosarcoma[J]. Expert review ofproteomics, 2014, 11(3): 331-343.
  • 2Zhang YH, Li HD, Li B, et al. Ginsenoside Rg3 induces DNA damage in haman osteosarcoma ceils and reduces MNNG-induced DNA damage and apoptosis in normal human cells [J]. Oncology reports, 2014, 31(2): 919-925.
  • 3Shangguan W J, Li H, Zhang YH. Induction of G2/M phase cell cycle arrest and apoptosis by ginsenoside Rf in human osteosareoma MG 63 cells through the mitochondrial pathway [J]. Oncology reports, 2014, 31(1): 305-313.
  • 4Zhang Y, Wei R, Zhu X, et al. Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro[J]. Anti-cancer drugs, 2012, 23(2): 212-219.
  • 5Quan L H, Min J W, Jin Y, et al. Enzymatic biotransformation of ginsenoside Rbl to compound K by recombinant glucosidase from Microbactcrium esteraromaticum [J]. Journal of agricultural and food chemistry, 2012, 60(14): 3776-3781.
  • 6Yu X, Zhou X, Fu C, et al. Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway [J]. Oncology reports, 2015, 34(3): 1129-1136.
  • 7Song Junmin,Liu Hongxiang,Li Zhen,Yang Chao,Wang Chaojie.Ginsenoside Rg3 inhibits colon cancer cell migration by suppressing nuclear factor kappa B activity[J].Journal of Traditional Chinese Medicine,2015,35(4):440-444. 被引量:13
  • 8Godoy D L, Betts-Obregon B S, Tsin A T. Ginsenoside-Rbl Inhibition of VEGF Release-Structure and Activity Relations (SAR) Perspective [J]. Medical hypothesis, discovery and innovation in ophthalmology, 2014, 3(2): 38.
  • 9Siraj F M, Natarajan S, Huq MA, et al. Structural investigation of ginsenoside Rf with PPAR major transcriptional factor of adipogenesis and its impact on adipocyte [J]. Journal of Ginseng Research, 2015, 39(2): 141-147.
  • 10Liang L D, He T, Du TW, et al. Ginsenoside Rg5 induces apoptosis and DNA damage in human cervical cancer cells [J]. Molecular medicine reports, 2015, 11(2): 940-946.

二级参考文献6

共引文献12

同被引文献77

引证文献9

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部